Benitec Biopharma Inc. Operating Income

Quick Answer

Benitec Biopharma Inc. reported Operating Income of -$41.77 million for fiscal year 2025.

Benitec Biopharma Inc. Operating Income — Annual History

Fiscal Year Operating Income YoY Change
2025 -$41.77M -85.7%
2024 -$22.49M -17.9%
2023 -$19.08M -6.9%
2022 -$17.85M -31.3%
2021 -$13.60M -64.2%
2020 -$8.28M -420.6%
2019 $2.58M

Quarterly Operating Income

Quarter Ending Operating Income YoY QoQ
December 31, 2025 -$13.38M -23.8% -36.5%
September 30, 2025 -$9.80M -69.3% +3.8%
March 31, 2025 -$10.19M -146.0% +5.7%
December 31, 2024 -$10.80M -56.0% -86.6%
September 30, 2024 -$5.79M +1.4% -39.8%
March 31, 2024 -$4.14M +4.6% +40.2%
December 31, 2023 -$6.93M -23.5% -17.9%
September 30, 2023 -$5.87M -28.3% -35.3%
  • Benitec Biopharma Inc. showed a decrease of -85.7% in Operating Income compared to the prior fiscal year.
  • Over the 2019–2025 period, Benitec Biopharma Inc.’s operating income has declined by 1716.9% (from $2.58 million to -$41.77 million).
  • The most recent figure is from Benitec Biopharma Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 22, 2025.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment